{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:52Z","timestamp":1786977472196,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00296-019-04453-y","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T10:26:50Z","timestamp":1570703210000},"page":"489-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9167-9204","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Arbel\u00e1ez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-1698","authenticated-orcid":false,"given":"Diana C.","family":"Quintero-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-0645","authenticated-orcid":false,"given":"Yesid","family":"Cuesta-Astroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Villadiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Gonz\u00e1lez-Buritic\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge M.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"4453_CR1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"23","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O et al (2015) Systemic sclerosis. Nat Rev Dis Prim 23:15002. \nhttps:\/\/doi.org\/10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Prim"},{"key":"4453_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH et al (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66:1625\u20131635. \nhttps:\/\/doi.org\/10.1002\/art.38390","journal-title":"Arthritis Rheumatol"},{"key":"4453_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/annrheumdis-2014-206386","volume":"75","author":"M Elhai","year":"2016","unstructured":"Elhai M, Avouac J, Walker UA et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75:163\u2013169. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2014-206386","journal-title":"Ann Rheum Dis"},{"key":"4453_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brandy","year":"1967","unstructured":"Brandy RO, Gal AE, Bradley RMB et al (1967) Enzymatic defect in Fabry\u00b4s disease. N Engl J Med 276:1163\u20131167. \nhttps:\/\/doi.org\/10.1056\/NEJM196705252762101","journal-title":"N Engl J Med"},{"key":"4453_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:1\u201349. \nhttps:\/\/doi.org\/10.1186\/1750-1172-5-30","journal-title":"Orphanet J Rare Dis"},{"key":"4453_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123:416\u2013427. \nhttps:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"4453_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH et al (2009) High incidence of the cardiac variant of fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450\u2013456. \nhttps:\/\/doi.org\/10.1161\/CIRCGENETICS.109.862920","journal-title":"Circ Cardiovasc Genet"},{"key":"4453_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340. \nhttps:\/\/doi.org\/10.1086\/504601","journal-title":"Am J Hum Genet"},{"key":"4453_CR9","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FMP Meier","year":"2012","unstructured":"Meier FMP, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355\u20131360. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2011-200742","journal-title":"Ann Rheum Dis"},{"key":"4453_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/jgf2.76","volume":"18","author":"T Kubo","year":"2017","unstructured":"Kubo T (2017) Fabry disease and its cardiac involvement. J Gen Fam Med 18:225\u2013229. \nhttps:\/\/doi.org\/10.1002\/jgf2.76","journal-title":"J Gen Fam Med"},{"key":"4453_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.rdc.2013.10.007","volume":"40","author":"JL Parks","year":"2014","unstructured":"Parks JL, Taylor MH, Parks LP, Silver RM (2014) Systemic sclerosis and the heart. Rheum Dis Clin North Am 40:87\u2013102. \nhttps:\/\/doi.org\/10.1016\/j.rdc.2013.10.007","journal-title":"Rheum Dis Clin North Am"},{"key":"4453_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409816661352","volume":"4","author":"A Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez A, Politei J (2016) Cardiac manifestation of Fabry disease. J Inborn Errors Metab Screen 4:1\u20139. \nhttps:\/\/doi.org\/10.1177\/2326409816661352","journal-title":"J Inborn Errors Metab Screen"},{"key":"4453_CR13","first-page":"28","volume":"20","author":"N Arias Mart\u00ednez","year":"2003","unstructured":"Arias Mart\u00ednez N, Barbado Hern\u00e1ndez FJ, P\u00e9rez Mart\u00edn G et al (2003) Fabry\u2019s disease associated with rheumatoid arthritis. Multisystemic crossroads. Ann Med Interna 20:28\u201330","journal-title":"Ann Med Interna"},{"key":"4453_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/0961203313497116","volume":"22","author":"A Nandagudi","year":"2013","unstructured":"Nandagudi A, Jury EC, Alonzi D et al (2013) Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry\u2019s disease. Lupus 22:1070\u20131076. \nhttps:\/\/doi.org\/10.1177\/0961203313497116","journal-title":"Lupus"},{"key":"4453_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1471-2369-15-157","volume":"15","author":"H Hanaoka","year":"2014","unstructured":"Hanaoka H, Hashiguchi A, Konishi K et al (2014) A rare association between Fabry\u2019s disease and granulomatosis with polyangiitis: a potential pathogenic link. BMC Nephrol 15:157. \nhttps:\/\/doi.org\/10.1186\/1471-2369-15-157","journal-title":"BMC Nephrol"},{"key":"4453_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3899\/jrheum.150726","volume":"43","author":"C Chatre","year":"2016","unstructured":"Chatre C, Filippi N, Roubille FPY (2016) Heart involvement in a woman treated with hydroxychloroquine for systemic lupus erythematosus revealing Fabry disease. J Rheumatol 43:997\u2013998. \nhttps:\/\/doi.org\/10.3899\/jrheum.150726","journal-title":"J Rheumatol"},{"key":"4453_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Van Den Hoogen","year":"2013","unstructured":"Van Den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"4453_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s004390050292","volume":"98","author":"D Germain","year":"1996","unstructured":"Germain D, Biasotto M, Tosi M, Meo T, Kahn APL (1996) Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase. A gene and detection of carriers in Fabry disease. Hum Genet 98:719\u2013726. \nhttps:\/\/doi.org\/10.1007\/s004390050292","journal-title":"Hum Genet"},{"key":"4453_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/humu.9327","volume":"25","author":"E Sch\u00e4fer","year":"2005","unstructured":"Sch\u00e4fer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25:412. \nhttps:\/\/doi.org\/10.1002\/humu.9327","journal-title":"Hum Mutat"},{"key":"4453_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","volume":"29","author":"N Seydelmann","year":"2015","unstructured":"Seydelmann N, Wanner C, St\u00f6rk S et al (2015) Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab 29:195\u2013204. \nhttps:\/\/doi.org\/10.1016\/j.beem.2014.10.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4453_CR21","first-page":"S48","volume":"28","author":"Y Allanore","year":"2010","unstructured":"Allanore Y, Meune C (2010) Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 28:S48\u2013S53","journal-title":"Clin Exp Rheumatol"},{"key":"4453_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/art.23463","volume":"58","author":"C Meune","year":"2008","unstructured":"Meune C, Avouac J, Wahbi K et al (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58:1803\u20131809. \nhttps:\/\/doi.org\/10.1002\/art.23463","journal-title":"Arthritis Rheum"},{"key":"4453_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4330\/wjc.v6.i7.585","volume":"6","author":"H Satoh","year":"2014","unstructured":"Satoh H (2014) Distribution of late gadolinium enhancement in various types of cardiomyopathies: significance in differential diagnosis, clinical features and prognosis. World J Cardiol 6:585. \nhttps:\/\/doi.org\/10.4330\/wjc.v6.i7.585","journal-title":"World J Cardiol"},{"key":"4453_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/rheumatology\/ket377","volume":"53","author":"A Vacca","year":"2014","unstructured":"Vacca A, Meune C, Gordon J et al (2014) Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatol 53:1172\u20131177. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ket377","journal-title":"Rheumatol"},{"key":"4453_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejrad.2013.02.014","volume":"82","author":"E Di Cesare","year":"2013","unstructured":"Di Cesare E, Battisti S, Di Sibio A et al (2013) Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). Eur J Radiol 82:268\u2013273. \nhttps:\/\/doi.org\/10.1016\/j.ejrad.2013.02.014","journal-title":"Eur J Radiol"},{"key":"4453_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/0003-4819-94-1-38","volume":"94","author":"NK Roberts","year":"1981","unstructured":"Roberts NK, Cabeen WR, Moss J et al (1981) The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 94:38\u201340. \nhttps:\/\/doi.org\/10.7326\/0003-4819-94-1-38","journal-title":"Ann Intern Med"},{"key":"4453_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J et al (2012) Trends in mortality in patients with systemic sclerosis over 40\u00a0years: a systematic review and meta-analysis of cohort studies. Rheumatology 51:1017\u20131026. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ker269","journal-title":"Rheumatology"},{"key":"4453_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00296-015-3382-2","volume":"37","author":"A Fern\u00e1ndez-Codina","year":"2017","unstructured":"Fern\u00e1ndez-Codina A, Sime\u00f3n-Aznar CP, Pinal-Fernandez I et al (2017) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 37:75\u201384. \nhttps:\/\/doi.org\/10.1007\/s00296-015-3382-2","journal-title":"Rheumatol Int"},{"key":"4453_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/rheumatology\/kew488","volume":"56","author":"LA Bissell","year":"2017","unstructured":"Bissell LA, Anderson M, Burgess M et al (2017) Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatol 56:912\u2013921. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kew488","journal-title":"Rheumatol"},{"key":"4453_CR30","unstructured":"HGMD\u00ae gene result (2018) \nhttp:\/\/www.hgmd.cf.ac.uk\/ac\/gene.php?gene=GLA\n\n. Accessed 15 Dec 2018"},{"key":"4453_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X et al (2017) The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 19:430\u2013438. \nhttps:\/\/doi.org\/10.1038\/gim.2016.122","journal-title":"Genet Med"},{"key":"4453_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128. \nhttps:\/\/doi.org\/10.1016\/j.ymgme.2007.09.013","journal-title":"Mol Genet Metab"},{"key":"4453_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/ehjci\/jex034","volume":"18","author":"G Habib","year":"2017","unstructured":"Habib G, Bucciarelli-Ducci C, Caforio ALP et al (2017) Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document. Eur Heart J Cardiovasc Imaging 18:1090\u20131121. \nhttps:\/\/doi.org\/10.1093\/ehjci\/jex034","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4453_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","volume":"96","author":"JS Shah","year":"2005","unstructured":"Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842\u2013846. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2005.05.033","journal-title":"Am J Cardiol"},{"key":"4453_CR35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/ehjci\/jeu080","volume":"15","author":"R Madonna","year":"2014","unstructured":"Madonna R, Cevik C, Cocco N (2014) Multimodality imaging for pre-clinical assessment of Fabry\u2019s cardiomyopathy. Eur Heart J Cardiovasc Imaging 15:1094\u20131100. \nhttps:\/\/doi.org\/10.1093\/ehjci\/jeu080","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4453_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2874902","volume":"2017","author":"A Rammos","year":"2017","unstructured":"Rammos A, Meladinis V, Vovas G, Patsouras D (2017) Restrictive cardiomyopathies: the importance of noninvasive cardiac imaging modalities in diagnosis and treatment\u2014a systematic review. Radiol Res Pract 2017:1\u201314. \nhttps:\/\/doi.org\/10.1155\/2017\/2874902","journal-title":"Radiol Res Pract"},{"key":"4453_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/RTI.0000000000000199","volume":"31","author":"F Muehlberg","year":"2016","unstructured":"Muehlberg F, Toepper A, Fritschi S et al (2016) Magnetic resonance imaging applications on infiltrative cardiomyopathies. J Thorac Imaging 31:336\u2013347. \nhttps:\/\/doi.org\/10.1097\/RTI.0000000000000199","journal-title":"J Thorac Imaging"},{"key":"4453_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-016-0233-6","volume":"18","author":"DP Deva","year":"2016","unstructured":"Deva DP, Hanneman K, Li Q et al (2016) Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 18:1\u201310. \nhttps:\/\/doi.org\/10.1186\/s12968-016-0233-6","journal-title":"J Cardiovasc Magn Reson"},{"key":"4453_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120:57\u201361. \nhttps:\/\/doi.org\/10.1016\/j.ymgme.2016.10.006","journal-title":"Mol Genet Metab"},{"key":"4453_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S et al (2014) Gene mutations versus clinically relevant phenotypes lyso-gb3 defines fabry disease. Circ Cardiovasc Genet 7:8\u201316. \nhttps:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000249","journal-title":"Circ Cardiovasc Genet"},{"key":"4453_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10545-007-0513-2","volume":"30","author":"P Martinez","year":"2007","unstructured":"Martinez P, Aggio M, Rozenfeld P (2007) High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis 30:365\u2013369. \nhttps:\/\/doi.org\/10.1007\/s10545-007-0513-2","journal-title":"J Inherit Metab Dis"},{"key":"4453_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000000780","volume":"94","author":"S Deshayes","year":"2015","unstructured":"Deshayes S, Auboire L, Jaussaud R et al (2015) Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in fabry disease. Med (United States) 94:1\u20135. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000000780","journal-title":"Med (United States)"},{"key":"4453_CR43","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749. \nhttps:\/\/doi.org\/10.1001\/jama.285.21.2743","journal-title":"JAMA"},{"key":"4453_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","volume":"37","author":"SM Rombach","year":"2014","unstructured":"Rombach SM, Smid BE, Linthorst GE et al (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis. J Inherit Metab Dis 37:341\u2013352. \nhttps:\/\/doi.org\/10.1007\/s10545-014-9677-8","journal-title":"J Inherit Metab Dis"},{"key":"4453_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","volume":"107","author":"M Motwani","year":"2012","unstructured":"Motwani M, Banypersad S, Woolfson P, Waldek S (2012) Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 107:197\u2013202. \nhttps:\/\/doi.org\/10.1016\/j.ymgme.2012.05.011","journal-title":"Mol Genet Metab"},{"key":"4453_CR46","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.3892\/etm.2018.5889","volume":"15","author":"Y Ouyang","year":"2018","unstructured":"Ouyang Y, Chen B, Pan X et al (2018) Clinical significance of plasma globotriaosylsphingosine levels in chinese patients with fabry disease. Exp Ther Med 15:3733\u20133742. \nhttps:\/\/doi.org\/10.3892\/etm.2018.5889","journal-title":"Exp Ther Med"},{"key":"4453_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H (2018) Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol 22:843\u2013849. \nhttps:\/\/doi.org\/10.1007\/s10157-017-1525-3","journal-title":"Clin Exp Nephrol"},{"key":"4453_CR48","doi-asserted-by":"publisher","first-page":"f153","DOI":"10.1093\/europace\/eux261","volume":"20","author":"S Baig","year":"2018","unstructured":"Baig S, Edward NC, Kotecha D et al (2018) Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace 20:f153\u2013f161. \nhttps:\/\/doi.org\/10.1093\/europace\/eux261","journal-title":"Europace"},{"key":"4453_CR49","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00296-018-4110-5","volume":"38","author":"SI Mavrogeni","year":"2018","unstructured":"Mavrogeni SI, Sfikakis PP, Dimitroulas T et al (2018) Prospects of using cardiovascular magnetic resonance in the identification of arrhythmogenic substrate in autoimmune rheumatic diseases. Rheumatol Int 38:1615\u20131621. \nhttps:\/\/doi.org\/10.1007\/s00296-018-4110-5","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04453-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04453-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04453-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:11:15Z","timestamp":1602198675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04453-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4453"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04453-y","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}